Recently, Shanghai Huihe Medical Technology Co., Ltd. (hereinafter referred to as Huihe Medical) announced the completion of its Series D financing round. This round was strategically led by China Taiping Healthcare Fund, with follow-on investment from its existing shareholder Sherpa Healthcare Fund II (Suzhou) Equity Investment Partnership (Limited Partnership) (hereinafter referred to as Sherpa). This marks another important milestone for Huihe Medical following the closing of its Series C+ financing in 2022, and attests to the capital market’s high recognition of the company’s innovative strength in the field of interventional therapy for structural heart disease.
Picture：From VB100

In recent years, insurance capital has emerged as a vital driving force for the development of the healthcare industry. As a quintessential representative of patient capital, insurance capital boasts distinctive strengths in long-term sustainability, stability and cross-cycle asset allocation, which are highly aligned with the healthcare industry’s inherent traits of long investment cycles and high capital input. Meanwhile, as a core payer in the healthcare sector, insurance institutions share an innate affinity with innovative medical device enterprises. By building a well-structured, holistic health management ecosystem underpinned by the integration of customers, payers, demand-side players and resource providers, they can achieve in-depth synergy between their core insurance business and the healthcare industry.
Huihe Medical has earned the strategic investment of China Taiping Healthcare Fund, an affiliate of China Taiping Insurance Group, thanks to its distinctive competitive edges and tremendous growth potential. The company holds industry-leading advantages in delivery systems, precision manufacturing, simulation modeling and automated production, and has a portfolio of independently developed, world-class commercialized products in the cardiovascular intervention field. Its core product—the globally pioneering K-Clip® Transcatheter Tricuspid Valve Repair System—replicates the classic surgical procedure to treat tricuspid regurgitation via minimally invasive surgery. Having obtained marketing approval from the National Medical Products Administration (NMPA) in March 2025, the product has now been rolled out for large-scale commercial application.
According to Vcbeat, there remains a substantial unmet clinical need in the field of structural heart disease. Data from the Chinese Circulation Journal shows that in 2023, the number of hospitals admitting inpatients with structural heart disease in China rose by 32.5% year on year, surging from 5,129 to 6,794. The volume of hospitalized patients treated for such conditions increased by 38.1%, rising from 3.39 million to 4.68 million. The stark disparity between the high morbidity rate and low intervention rate of structural heart disease has attracted growing attention from the global cardiology community. Huihe Medical’s independently developed original products have delivered groundbreaking solutions to address this critical clinical gap.

Capital Insights & Corporate Voices

China Taiping Healthcare Fund commented: "In our investment practice, we have always adhered to a research-driven approach and maintained a sharp focus on the world’s most innovative and competitive products. Huihe Medical’s original innovative interventional medical devices, represented by the K-Clip®, have pioneered an entirely new surgical technique for tricuspid annuloplasty and repair. This product is poised to become a commercially viable tricuspid annuloplasty and repair solution on a global scale in the future. We look forward to Huihe Medical’s continuous R&D iteration based on its annuloplasty repair technology and the 'One Valve, Dual Repair' philosophy, bringing benefits to patients worldwide."
Cai Daqing, Founding Managing Partner of Sherpa Investment, stated: "The completion of this Series D financing round will provide Huihe Medical with sufficient financial support, abundant insurance channel resources and medical institution networks to accelerate the commercialization and market penetration of the K-Clip® and other flagship products in both China and overseas markets, laying a solid foundation for the company’s revenue growth. Sherpa Investment has consistently been optimistic about Huihe Medical’s R&D capabilities and commercialization prospects, and has resolutely made multiple follow-up investments since our initial funding in the company."

Lin Lin, Chairman of Huihe Medical, said: "Huihe Medical’s successful closing of the Series D financing round represents a key strategic deployment by China Taiping Healthcare Fund in the field of interventional therapy for structural heart disease. It also stands as a compelling example of insurance capital empowering the development of new-quality productive forces and supporting technological self-reliance and innovation. This financing has injected strong impetus into the company’s commercialization progress and global expansion drive. Meanwhile, we would like to express our sincere gratitude to our long-standing shareholder Sherpa Investment for its consistent and steadfast support and recognition over the years. Going forward, Huihe Medical will continue to forge ahead with breakthrough innovations in the cardiovascular intervention field, delivering more minimally invasive and safer treatment solutions for patients, providing more user-friendly and controllable surgical tools for clinicians, and contributing Chinese wisdom and Chinese solutions to the global healthcare cause."

Focus on Shanghai Huihe Medical Technology Co., Ltd
Shanghai Huihe Medical Technology Co., Ltd. (referred to as Huihe Medical) is a high-tech enterprise dedicated to the research and development, manufacturing and commercialization of cardiovascular interventional medical devices, with its headquarters located in Songjiang District, Shanghai. Driven by the principles of integrated medicine and engineering and original R&D and innovation, Huihe Medical is committed to bringing high-end medical devices designed and made in China to the global market.
Focus on China Taiping Healthcare Fund & Sherpa Healthcare Fund II (Suzhou)
China Taiping Healthcare Fund was established in 2021 with a registered capital scale of RMB 10 billion, and China Taiping Innovation Investment Management Co., Ltd. acts as its fund manager. The Fund focuses on sectors including biopharmaceuticals, medical devices and diagnostics, medical services, biotechnology and medical informatization, and also extends its reach to related fields such as health technology and health consumption. It is committed to building a distinctive "Insurance + Healthcare, Elderly Care & Wellness" ecosystem with Taiping’s unique characteristics.
Equity Investment Partnership (Limited Partnership)
Sherpa Investment is a fund management company dedicated to healthcare investments in the early and growth stages of enterprises. Adhering to the philosophy of "investing early, investing in innovation, and investing with precision", Sherpa leverages its long-established industry insights and advantageous resources to build an investment portfolio focusing on major therapeutic areas with substantial unmet critical clinical needs. Its investment coverage spans key sectors including genetic technologies and their applications, biopharmaceuticals, medical devices and diagnostics, and digital healthcare. The firm expands its investment reach along the industrial chain and across upstream and downstream segments to foster synergies among portfolio companies, with a well-established investment footprint in both China and the United States.